Journal of Clinical Pharmacy and Therapeutics · 2017 · 14 citations · 8 references
PharmacyNeurologyToxicologyHeavy Metal ToxicologyPoisoning DiagnosisPoisoning ManagementAcute Heavy Metal PoisoningArsenic PoisoningArsenic ToxicologyPeripheral Neuropathy ManagementArsenic Chelation TherapyArsenic Poisoning ManagementArsenic Poisoning TreatmentClinical Symptoms
WHAT IS KNOWN AND OBJECTIVE: Massive acute arsenic poisoning is rare yet potentially life-threatening. 2,3-dimercaptopropane-1-sulphonate (DMPS) appears to have the appropriate chelating property. However, clinical experience on the use of DMPS in massive arsenic poisoning is limited. CASE DESCRIPTION: A 37-year-old woman attempted suicide by ingesting 37.5 g of arsenic trioxide. DMPS was promptly initiated based on history and clinical symptoms. The patient recovered completely, with no complications or side effects of the therapy. WHAT IS NEW AND CONCLUSION: TDMPS is useful for the treatment of massive acute arsenic poisoning.
8
H. Vasken Aposhian, Baoshan Zheng, Mary M. Aposhian et al. · Toxicology and Applied Pharmacology · 2000 · 138 citations
Antonio Dueñas‐Laita, Manuel Pérez‐Miranda, María A González-López et al. · The Lancet · 2005 · 36 citations